Roadmap for Transforming Obesity Disease Management

America's $1.4 trillion obesity crisis affects 40% of adults—96% of whom don't receive care. Our new framework provides 36 actionable solutions across three integrated areas to transform systemic barriers into coordinated healthcare solutions.

Image
Image

Financing and Reimbursement of Cures in the US

The FoCUS Project targets the need for new innovative financing and reimbursement models for curative medicines in the US that ensure (1) patient access for needed treatments; (2) affordability for public and private payers; and (3) the sustainability of innovation by manufacturers.

From Fragmentation to Integration: A Multi-Stakeholder Framework for Obesity Disease Management

The United States faces a paradox: obesity affects 40% of adults and costs $1.4 trillion annually, yet 96% of people with obesity never receive medical treatment. Traditional approaches have failed because they address isolated aspects of a complex, system-wide problem spanning provider bias, fragmented care delivery, misaligned incentives, and societal stigma.

NEWDIGS launched this initiative in early 2024 to develop the first comprehensive, systems-level solution. Over 18 months, we convened healthcare providers, insurers, pharmaceutical companies, patient advocates, and policymakers in intensive Design Labs to map challenges and pressure-test solutions. This collaborative approach ensured every stakeholder's constraints and motivations were understood and addressed.

The result is a practical roadmap with three integrated solution areas and 36 specific action components. Rather than theoretical recommendations, these are implementable strategies that recognize how different stakeholders must work together for sustainable change.

Moving forward, we're expanding the coalition of implementing organizations, and developing stakeholder-specific toolkits. Our goal is to create a movement where obesity is treated as the chronic disease it is, with coordinated care that works for patients, providers, and the entire healthcare system.

Join FoCUS

Successfully meeting the emerging challenges of financing durable/potentially curative therapies will take the hands-on engagement of all stakeholders in the healthcare innovation ecosystem.

Organizations that join FoCUS have the opportunity to shape the immediate and long-term future of both medical innovation and financial solutions to appropriate patient access for durable/curative therapies.

Download the FoCUS Project Prospectus (PDF)

FoCUS Partners

FoCUS partners supported the project with financial or in-kind donations. Partners included:

Beth Israel Deaconess Medical Center (BIDMC)
Bill & Melinda Gates Foundation
Blue Cross Blue Shield Association
bluebird bio
Bristol-Myers Squibb
Canadian Agency for Drugs and Technologies in Health (CADTH)
Canadian Organization for Rare Disorders (CORD)
European Federation of Pharmaceutical Industries and Associations (EFPIA)
European Organisation for Rare Diseases (EURORDIS)
European Medicines Agency (EMA)
European network for Health Technology Assessment (EUnetHTA)
Food and Drug Administration (FDA, USA)
Friends of Cancer Research
Harvard Medical School
Harvard School of Public Health
Health Canada
Innovative Medicines Initiative (IMI)
Johnson & Johnson
Massachusetts General Hospital 
Medicines and Healthcare products Regulatory Agency (MHRA)
National Healthcare Institute (ZIN, the Netherlands)
National Organization for Rare Disorders (NORD)
National Institute for Health and Care Excellence (NICE)
Pfizer
Sanofi